Nā ʻano o ka Immunotherapy no ka mālama ʻana i ka maʻi kanesa
ʻO ka Immunotherapy kahi ʻano lapaʻau maʻi kanesa e hoʻohana ana i ka ʻōnaehana pale e ʻike a hakakā i nā hunaola kanesa. ʻAʻole e like me ka chemotherapy, ka mea e hoʻouka i nā hunaola e māhele wikiwiki ana, a i ʻole radiotherapy, ka mea e hōʻino ana i ka DNA hunaola tumor me ka radiation, hana ka immunotherapy ma ka "hoʻoikaika ʻana," "kuhikuhi ʻana," a i ʻole "hoʻokuʻu ʻana i nā paleki" ma ka pane pale, e ʻoi aku ka maikaʻi o ke kino i ka luku ʻana i ka maʻi kanesa. I nā makahiki i hala iho nei, ua lilo ka immunotherapy i mea holomua nui i ka oncology no ka mea hiki iā ia ke hāʻawi i nā pane paʻa i kekahi mau maʻi, ʻoiai i nā maʻi kanesa i paʻakikī mua ke mālama.
Eia nō naʻe, ʻaʻole kūpono ka immunotherapy no nā ʻano maʻi kanesa āpau a i ʻole nā maʻi āpau. Hiki ke ʻokoʻa nā hopena ʻaoʻao mai nā lāʻau lapaʻau maʻamau, e pili pinepine ana i ka hoʻoulu nui ʻana o ka ʻōnaehana pale. No laila, ʻo ke koho ʻana o ka immunotherapy e pili pinepine ʻia ma ke ʻano o ke kanesa, ke kahua o ka maʻi, ke kūlana o ka mea maʻi, a me nā biomarkers kikoʻī. Eia nā ʻano immunotherapy maʻamau i hoʻohana ʻia i ka mālama ʻana i ka maʻi kanesa.
1. Nā mea pale i ka pale ʻana i ka maʻi (Nā mea pale i ka pale ʻana i ka maʻi)
ʻO kekahi o nā ʻano immunotherapy kaulana loa ʻo ia nā mea hoʻopaʻa i ka pale ʻana i ka maʻi. Loaʻa i ka ʻōnaehana pale nā "checkpoints," nā ʻano hana kūlohelohe e pale ai i nā pane pale nui e hiki ke hōʻino i nā ʻiʻo ponoʻī o ke kino. Hoʻohana pinepine nā cell cancer i kēia mau checkpoints e "peʻe" mai ka hoʻouka ʻia ʻana e nā cell T (nā cell immune pepehi kanaka).
Hana nā mea hoʻopaʻa checkpoint ma ke kāohi ʻana i nā protein checkpoint kikoʻī, e ʻae ana i nā cell T e hoʻāla hou a hoʻouka i nā cell cancer. ʻO nā pahuhopu ʻelua maʻamau:
– PD-1/PD-L1 (Programmed Death-1 / Ligand-1): Hiki i nā hunaola maʻi kanesa ke hōʻike i ka PD-L1 e "hoʻopau" i nā hunaola T. Hiki i nā lāʻau lapaʻau e kāohi ana i ka PD-1 a i ʻole PD-L1 ke kōkua i ka wehe hou ʻana i ka hana o nā hunaola T.
– CTLA-4 (Cytotoxic T-Lymphocyte–Associated Protein 4): He mea kāohi ʻo CTLA-4 i ka hoʻāla ʻana o nā pūnaewele T, ʻoiai hoʻi i nā pae mua o ka pane ʻana o ka pale ʻana.
Hoʻohana ʻia nā mea hoʻopaʻa Checkpoint e mālama i nā ʻano maʻi kanesa like ʻole, me ka melanoma, ka maʻi kanesa māmā, ka maʻi kanesa puʻupaʻa, ka maʻi kanesa ʻōpū, a me kekahi mau maʻi kanesa poʻo a me ka ʻāʻī. ʻO ka pōmaikaʻi o kēia lāʻau lapaʻau ka hiki ke loaʻa kahi pane lōʻihi, akā ʻo nā pilikia e pili ana i nā hopena ʻaoʻao autoimmune e like me ka colitis, pneumonitis, nā maʻi thyroid, a me ka hepatitis autoimmune.
2. Lapaʻau CAR T-Cell (Lapaʻau CAR T-Cell)
He immunotherapy pilikino loa ka CAR T-cell therapy. Ma kēia therapy, lawe ʻia nā T cell o ka mea maʻi mai ke koko a laila hoʻololi ʻia i loko o ka hale hana e loaʻa ai kahi receptor kūikawā i kapa ʻia ʻo Chimeric Antigen Receptor (CAR). Ua hoʻolālā ʻia kēia receptor e ʻike i nā antigens kikoʻī ma luna o ka ʻili o nā cell cancer. Ke hoʻololi ʻia a hoʻonui ʻia, hoʻihoʻi ʻia nā T cell i ke kino o ka mea maʻi e ʻimi a luku i nā cell cancer.
Ua hōʻike ʻia ka holomua nui o ka CAR T-cell therapy, ʻoiai ma kekahi mau maʻi kanesa koko, e like me:
- ka maʻi leukemia lymphoblastic koʻikoʻi (ALL) i kekahi mau hihia,
- kekahi mau lymphoma non-Hodgkin,
- myeloma lehulehu ma kekahi mau hōʻailona.
Eia nō naʻe, hiki i kēia lāʻau lapaʻau ke hana i nā hopena ʻaoʻao koʻikoʻi, e like me ka Cytokine Release Syndrome (CRS), ka mea e hoʻoulu ai i ke kuni kiʻekiʻe a me ke koko haʻahaʻa, a me kekahi mau maʻi neurological. Eia kekahi, he mau pilikia ke kumukūʻai a me ka loaʻa ʻana o nā pono ma muli o ke kaʻina hana paʻakikī.
3. Nā lāʻau pale monoclonal
ʻO nā antibodies monoclonal he mau protein synthetic i hoʻolālā ʻia e hoʻopili i nā pahuhopu kikoʻī ma nā cell cancer. Ma ka "lepili ʻana" i nā cell cancer, kōkua nā antibodies i ka ʻōnaehana pale e ʻike i nā tumors a hoʻopilikia paha i nā hōʻailona ulu ʻana o ka maʻi kanesa.
Aia kekahi mau ʻano hana a nā antibodies monoclonal i ka maʻi kanesa:
1. Nā antibodies i kuhikuhi ʻia e ka mea hoʻokipa: kāohi i nā hōʻailona ulu i loko o nā hunaola kanesa.
2. Nā antibodies e hoʻoulu ai i ka luku ʻia e ka ʻōnaehana pale: huki i nā pūnaewele pale e hoʻouka i nā pūnaewele i hōʻailona ʻia.
3. Antibody-drug conjugate (ADC): lawe nā antibodies i ka "uku" o nā lāʻau chemotherapy i nā cell cancer i ʻoi aku ka kikoʻī.
4. Radioimmunotherapy: lawe nā antibodies i nā mea radioactive i ka puʻupuʻu.
Hoʻohana nui ʻia nā antibodies monoclonal e mālama i nā ʻano maʻi kanesa like ʻole, me ke kanesa umauma, lymphoma, ke kanesa colorectal, a me nā mea ʻē aʻe. ʻOkoʻa nā hopena ʻaoʻao, mai nā hopena infusion a me nā ʻulaʻula ʻili a hiki i ka hōʻino ʻana o nā kino, ma muli o ka pahuhopu a lākou e kuhikuhi ai.
4. Nā lāʻau pale maʻi kanesa
ʻO ka pahuhopu o nā lāʻau pale maʻi kanesa ke hoʻoulu i ka ʻōnaehana pale e ʻike i nā antigens kanesa. ʻAʻole e like me nā lāʻau pale no ka pale ʻana i nā maʻi lele, hāʻule nā lāʻau pale kanesa i ʻelua mau māhele ākea:
– Nā lāʻau pale: pale i nā maʻi kanesa i hoʻokumu ʻia e kekahi mau maʻi. ʻO nā hiʻohiʻona kaulana loa ʻo ia ka lāʻau pale HPV, kahi e hōʻemi ai i ka pilikia o ke kanesa cervical a me kekahi mau maʻi kanesa poʻo a me ka ʻāʻī, a me ka lāʻau pale hepatitis B, kahi e hōʻemi ai i ka pilikia o ke kanesa ate.
– Nā lāʻau pale therapeutic: hāʻawi ʻia i nā poʻe maʻi i loaʻa mua i ka maʻi kanesa e kōkua i ka ʻōnaehana pale e hoʻouka i ka puʻupuʻu.
Hoʻopili pinepine nā lāʻau lapaʻau i nā antigens kūikawā i ka puʻupuʻu o ka mea maʻi a i ʻole nā antigens maʻamau i kekahi mau ʻano maʻi kanesa. Hiki ke ʻokoʻa nā pane, a ke hoʻomau nei ka noiʻi e hoʻomaikaʻi i ka pono, me ka hoʻohana ʻana i nā hui pū ʻana o nā checkpoint inhibitor.
5. Ka Lapaʻau Cytokine
He mau molekala hōʻailona nā cytokines a nā pūnaewele pale e hoʻohana ai e kamaʻilio a hoʻoponopono i nā pane pale. I ka lāʻau lapaʻau maʻi kanesa, hiki ke lawelawe ʻia kekahi mau cytokines e hoʻoikaika i ka hana o ka ʻōnaehana pale.
ʻO nā hiʻohiʻona o nā cytokines i hoʻohana nui ʻia:
– Interleukin-2 (IL-2): hiki ke hoʻoulu i ka ulu ʻana o nā pūnaewele T a me nā pūnaewele NK (pepehi kanaka kūlohelohe). Ua hoʻohana ʻia ia i kekahi mau maʻi ʻaʻai puʻupaʻa a me nā melanomas.
- Interferon alpha: hiki ke hoʻoikaika i ka pane pale a loaʻa iā ia nā hopena antiproliferative i kekahi mau maʻi kanesa.
Hiki ke kūpono ka lāʻau lapaʻau cytokine i kekahi mau maʻi, akā pinepine ka hopena ʻaoʻao o ke kino e like me ke kuni, ka luhi nui, ke koko haʻahaʻa, a me ka hana ʻino o ke kino, no laila ua koho nui ʻia kona hoʻohana ʻana a ua pani pinepine ʻia e nā lāʻau lapaʻau pale kino kikoʻī.
6. Ka Lapaʻau ʻana i ka maʻi Oncolytic
Hoʻohana ka lāʻau lapaʻau maʻi oncolytic i nā maʻi i hoʻololi ʻia e hoʻopili a luku i nā hunaola maʻi kanesa, ʻoiai e "hoʻāla" ana i ka ʻōnaehana pale e ʻike i ka puʻupuʻu. Ke wāwahi ka maʻi i nā hunaola maʻi kanesa, hoʻokuʻu ʻia nā antigens tumor, e hoʻoulu ai i kahi pane pale ākea.
He mea hoihoi kēia lāʻau lapaʻau no ka mea hana ia ma o ʻelua mau ʻano hana: ka luku pololei ʻana i nā hunaola puʻupuʻu a me ka hoʻoulu ʻana i ka ʻōnaehana pale maʻi kanesa. Hoʻokele pinepine ʻia ia ma o ka hoʻokomo pololei ʻana i loko o ka puʻupuʻu. Ke hoʻomau nei ka noiʻi e hoʻonui i kona hoʻohana ʻana ma nā ʻano maʻi kanesa like ʻole a e hoʻohui pū me nā mea pale checkpoint no kahi pane ikaika.
7. TIL Therapy a me nā Immunotherapy Cell Adoptive ʻē aʻe
Ma waho aʻe o CAR T, aia kekahi mau ʻano hana ʻē aʻe i kapa ʻia ʻo adoptive cell therapy, e like me ka tumor-infiltrating lymphocytes (TIL) therapy. I ka TIL therapy, lawe nā kauka i nā cell immune i loaʻa mua i loko o ka ʻiʻo tumor (nā lymphocytes e "infiltrate" i ka tumor), hoʻonui iā lākou i loko o ka hale hana, a laila hoʻihoʻi iā lākou i ka mea maʻi. No ka mea ua "hoʻomaʻamaʻa ʻia" kēia mau cell e ʻike i ke kaiapuni tumor, hiki i kēia therapy ke kūpono i kekahi mau hihia, ʻoi aku hoʻi i loko o ka pōʻaiapili o ka noiʻi a me kekahi mau kikowaena kanesa.
Aia kekahi mau ʻano hana i ka ʻenekinia ʻana i nā pūnaewele T me nā mea loaʻa ʻē aʻe (e laʻa, nā pūnaewele T i hana ʻia e TCR), ka mea e kuhikuhi ana i nā antigens tumor ma o kahi ʻano ʻike ʻokoʻa ma mua o CARs.
ʻO ka Immunotherapy Hui Pū ʻIa a me nā Pilikia o ka Wā e Hiki Mai Ana
I ka hana lapaʻau, hoʻohui pinepine ʻia ka immunotherapy me ka chemotherapy, radiotherapy, targeted therapy, a i ʻole ka hui pū ʻana o nā immunotherapies. ʻO ka pahuhopu ka hoʻonui ʻana i ka manawa kūpono o ka pane ʻana, lanakila i ke kūʻē, a hoʻonui i ka nui o nā maʻi e hiki ke pōmaikaʻi.
Eia nō naʻe, aia nō nā pilikia koʻikoʻi, e like me:
- ʻaʻole pane nā mea maʻi āpau,
- pono ka wānana pane i nā biomarkers pololei (e.g. PD-L1 expression, tumor mutational burden, MSI-high i kekahi mau maʻi kanesa),
- pono e nānā pono ʻia nā hopena ʻaoʻao autoimmune,
- he pilikia mau ke komo ʻana a me ke kumukūʻai o ka mālama ʻana ma nā wahi he nui.
Pani
Ua hoʻololi ka Immunotherapy i ke ʻano o ka mālama ʻana i ka maʻi kanesa ma ka hāʻawi ʻana i kahi ala hou e hoʻohana ai i ka mana o ka ʻōnaehana pale. Loaʻa kēia mau koho mai nā mea pale checkpoint, CAR T-cell therapy, monoclonal antibodies, cancer vaccines, cytokine therapy, oncolytic viruses, a me nā adoptive cell therapies e like me TILs. Loaʻa i kēlā me kēia ʻano hana nā pono, nā palena, a me nā hōʻailona. No laila, pono e hana ʻia nā hoʻoholo e pili ana i ka immunotherapy me ke kūkākūkā ʻana me kahi oncologist, e noʻonoʻo ana i ke ʻano o ka maʻi kanesa, ke kūlana o ka mea maʻi, a me nā biomarkers pili. Me ka hoʻomau ʻana o ka noiʻi, manaʻo ʻia e ʻoi aku ka maikaʻi o ka immunotherapy, palekana, a ʻoi aku ka nui o ka hiki ke loaʻa i nā mea maʻi kanesa.
